When is Samay the better choice?

The sensing method is genuinely novel, projecting low frequency sound into the lungs and analysing the returning signal, so it creates a measurement that does not otherwise exist outside a pulmonary function laboratory. Evidence is stronger than most companies at this stage and appropriately caveated, including a study with a defined patient population. Scope is narrow and clearly stated, respiratory disease specifically, rather than a general monitoring claim.

When is VUNO the better choice?

It predicts in hospital cardiac arrest within a day from four vital signs the ward already charts, so nothing new has to be bought or worn. Independent multicentre validation across several tertiary hospitals addresses site level generalisability better than most deterioration models here. Inputs and outputs are stated precisely, four named vital signs producing a bounded score over a defined horizon.

Samay vs VUNO

Last VerifiedAugust 4, 2026

Verdict

Two very different bets on where clinical signal comes from. Samay builds a chest worn device that projects low frequency sound into the lungs and reads what returns, creating a respiratory measurement that currently requires a pulmonary function laboratory, and it is still at development stage with no clearance evidenced. VUNO predicts in hospital cardiac arrest from four vital signs the ward already charts, with independent multicentre validation behind it and nothing new to buy. For a hospital today, VUNO is deployable and Samay is a technology to watch. The question Samay must eventually answer is whether its acoustic signal quality varies with body habitus, which is the same class of problem as pigmentation in optical measurement and equally unpublished.

Select Samay if

The sensing method is genuinely novel, projecting low frequency sound into the lungs and analysing the returning signal, so it creates a measurement that does not otherwise exist outside a pulmonary function laboratory.
Evidence is stronger than most companies at this stage and appropriately caveated, including a study with a defined patient population.
Scope is narrow and clearly stated, respiratory disease specifically, rather than a general monitoring claim.

Select VUNO if

It predicts in hospital cardiac arrest within a day from four vital signs the ward already charts, so nothing new has to be bought or worn.
Independent multicentre validation across several tertiary hospitals addresses site level generalisability better than most deterioration models here.
Inputs and outputs are stated precisely, four named vital signs producing a bounded score over a defined horizon.

Attribute Matrix

Side by Side

Axis	S Samay	V VUNO
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Remote Monitoring & Chronic Care page.

Bayesian Health vs VUNO→Ceribell vs VUNO→AccurKardia vs Biobeat→AccurKardia vs Ceribell→Biobeat vs Cadence→Cadence vs Dimer Health→

Disclosure

These sit at different stages and that should not be blurred: one is a development stage device described in prototype terms with no clearance evidenced, the other is a deployed model with published multicentre validation. The device raises a specific unanswered question about whether signal quality and model accuracy vary with body habitus, which is the acoustic equivalent of the pigmentation problem, and no subgroup data is published. VUNO's validation is Korean, so a United States buyer should ask what performance looks like in a population with different baseline vital sign distributions and escalation practices.